CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB) Meeting Abstract


Authors: Reck, M.; Hellmann, M. D.; Paz-Ares Rodriguez, L.; Ramalingam, S. S.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Borghaei, H.
Abstract Title: CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB)
Meeting Title: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
Journal Title: Oncology Research and Treatment
Volume: 41
Issue: Suppl. 4
Meeting Dates: 2018 Sep 28-Oct 2
Meeting Location: Vienna, Austria
ISSN: 2296-5270
Publisher: S. Karger AG  
Date Published: 2018-09-01
Start Page: 268
End Page: 269
Language: English
ACCESSION: WOS:000446816500654
PROVIDER: wos
PUBMED: 30261496
DOI: 10.1159/000492737
Notes: Meeting Abstract: V844 -- Source: Wos
Altmetric Score
MSK Authors
  1. Matthew David Hellmann
    172 Hellmann